Addex Therapeutics Ltd (SWX: ADXN)
Health Care · Pharmaceuticals · CH
CHF0.04
-10.71% today · -39.0% 1Y
Addex Therapeutics Ltd (SWX: ADXN) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $5.21M and employs 3 people.
Over the last twelve months the share price has lost 39.0%, trading between 0.03 and 0.09.
Tweenvest scores Addex Therapeutics Ltd across four factors: quality 26/100, value 49/100, growth 0/100. Its strongest factor is value.
ADXN price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $5.21M
- Revenue (TTM)
- $136.51K
- P/E
- —
- EPS
- -0.06
- Dividend yield
- —
- Beta (5Y)
- 2.00
- 52-week high
- CHF0.09
- 52-week low
- CHF0.03
- Avg volume (3M)
- —
- Shares outstanding
- 119.32M
- Employees
- 3
- Next earnings
- —
About Addex Therapeutics Ltd
Addex Therapeutics Ltd, a biopharmaceutical company in its development phase, specializes in the discovery, progression, and commercialization of small-molecule pharmaceutical products designed to address central nervous system (CNS) conditions. Based in Geneva, Switzerland, the firm's core research centers on identifying oral small molecule allosteric modulators that interact with G-protein coupled receptors. Its leading clinical programs feature Dipraglurant, intended for the treatment of levodopa-induced dyskinesia in Parkinson's disease and dystonia; ADX71149, targeting epilepsy and various other neurological disorders; and GABAB PAM, developed to combat addiction. Addex has established strategic licensing and collaborative partnerships with organizations including Janssen Pharmaceuticals Inc., Indivior PLC, and The Charcot–Marie–Tooth Association. Founded in 2002, the company changed its name from Addex Pharmaceuticals Ltd to its current designation in March 2012.
- ISIN
- CH0029850754
- Founded
- 2002
- Listed since
- May 22, 2007
- Exchange
- SIX Swiss Exchange
- Currency
- CHF
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,255.40 | +0.88% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $271.37 | +0.42% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $152.55 | +2.39% |
| Roche Holding AGSWX: ROP | $373.91B | CHF370.40 | -1.38% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £121.48 | -0.76% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $28.15 | +0.29% |
Figures last refreshed Aug 18, 2026.